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ABSTRACT
Background. The incidence of type 2 diabetes mellitus 
(T2DM) has increased over the past years and early 
identification and management of its complications 
especially diabetic kidney disease (DKD) is of great 
importance. T2DM and DKD are of multifactorial etio­
logy with contribution of genetic and environmental 
factors. We aimed to study the expression of ABCC8 
and Notch 2 genes in patients with T2DM and to find 
their association with DKD.
Methods. The present work was carried on 80 patients 
with T2DM (40 with DKD and 40 without DKD) and 
40 healthy subjects as a control group. Real time 
polymerase chain reaction was used to assess gene 
expression. 
Results. Altered expression of ABCC8 and Notch 2 
genes were found in patients with T2DM compared 
to control group. ABCC8 expression had significant 
positive correlation with HbA1c while Notch 2 expres­
sion had significant positive correlation with fasting 
plasma glucose and HbA1c. Notch 2 expression was 
significantly higher in patients with DKD compared to 
those without DKD. Multivariate regression analysis 
showed that Notch 2 expression had independent 
relation with increased urinary albumin excretion and 
reduced estimated glomerular filtration rate. ABCC8 
gene expression did not show significant difference 
between diabetic patients with DKD compared to 
those without DKD.
Conclusion. Increased expression of ABCC8 and Notch 2 
genes may play a role in pathogenesis of T2DM. 
Overexpression of Notch 2 gene may have a role in 
the development of albuminuria and DKD in patients 
with T2DM which may represent a possible diagnostic 
tool and a possible therapeutic target. (Clin Diabetol 
2020; 9; 5: 306–312)
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Introduction
Diabetes mellitus (DM) is a major health problem 
worldwide [1]. It is estimated that more than 400 mil-
lion adults had DM in 2019 which is predicted to reach 
700 million by 2045 [2]. Egypt is considered among 
the world top 10 countries in the world regarding the 
number of patients with DM [2].
Type 2 diabetes mellitus (T2DM) accounts for about 
90–95% of all cases of diabetes [3]. T2DM is considered 
a heterogeneous disease caused by interaction between 
genetics and environmental factors [4]. The damage 
precipitated by hyperglycemia on the human vascular 
tree is the major source of morbidity and mortality in 
T2DM due to functional and structural organ damage 
as a result of changes in the vascular system [5].
Diabetic kidney disease (DKD) is a leading cause of 
end stage renal disease (ESRD) worldwide and more 
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than 80% of cases of ESRD globally are caused by dia-
betes or hypertension, or a combination of both [2]. 
DKD may be present at diagnosis of T2DM and the 
presence of DKD markedly increases cardiovascular risk 
in patients with DM [6, 7]. 
Diagnosis of DKD is usually made based on the pres-
ence of albuminuria and/or reduced eGFR in the absence 
of symptoms or signs of other primary causes of kidney 
damage [6]. In light of the high prevalence of T2DM and 
its deleterious effect on the kidney, early detection and 
management of DKD are of great clinical importance.
ATP binding cassette, subfamily C, member 8 
(ABCC8) gene provides instructions for making the 
sulfonylurea receptor 1 (SUR1) protein [8]. The SUR1 
protein is a subunit of the ATP-sensitive potassium 
channel that controls the secretion of insulin out of 
beta cells of the pancreas into the bloodstream [9].
Notch 2 gene provides instructions for making 
Notch 2 protein which is a member of the Notch fam-
ily of receptors [10]. Notch 2 receptor is expressed in 
multiple cells and tissues including the pancreas, the 
liver and the kidney [11]. 
Studies have discovered multiple variants of genes 
associated with T2DM but the influence of most of 
these genes on the disease and on DKD is unclear [12]. 
Discoveries concerning the genetics of T2DM and DKD 
may have clinical implications by using these genes as 
diagnostic or therapeutic targets [13]. 
In the highlight of the role of genetic factors in 
the pathogenesis of T2DM and DKD, we aimed in 
this study to investigate the expression of ABCC8 and 
Notch 2 genes in Egyptian patients with T2DM and to 
investigate their association with DKD in these patients.
Methods
This study was conducted on 80 patients with 
T2DM who fulfilled the diagnostic criteria of Ameri-
can Diabetes Association (ADA) of T2DM [3]. The 
patients were divided into two groups, the first group 
included 40 patients with DKD who fulfilled the criteria 
of ADA for diagnosis of DKD (based on the presence 
of albuminuria and/or reduced eGFR with no evidence 
of primary causes of renal damage) [6] and the second 
group included 40 patients without DKD. The cases 
were recruited from the outpatient clinic of diabetes 
in Alexandria Main University Hospital. 
Patients with type 1 diabetes, gestational diabetes, 
hepatic or cardiac disease, hematological disorders 
and malignancies, history of hemodialysis or renal 
transplantation, infection, other acute or chronic au-
toimmune or metabolic diseases and patients using 
nephrotoxic drugs or corticosteroids were excluded 
from this study.
The study also included another 40 healthy subjects 
who volunteered to join this study as a control group 
and informed consent was obtained from all the indi-
viduals in this study.
To all the studied subjects full history was taken 
with special emphasis on the duration of diabetes, 
drug history with emphasis on antidiabetic drugs, 
antihypertensive drugs, corticosteroids in addition to 
any nephrotoxic drugs and presence of any chronic 
diseases especially any renal disorder.
Complete physical examination was done includ-
ing: heart rate, blood pressure measurement, complete 
cardiac examination, complete chest examination, 
measuring anthropometric parameters including body 
mass index (BMI) which was calculated as weight/ 
/height2 in meter and waist circumference (WC) which 
was measured at midpoint between the highest point 
of the iliac crest and lowest point of costal margin at 
the end of normal expiration.
Laboratory investigations
Early morning urine sample was obtained for com-
plete urine analysis and assessment of urinary albumin 
to creatinine ratio.
Blood sampling: sampling was done in the morning 
(8.00–10.00 am) after an overnight fast of 10 hours. 
9 milliliters of venous blood were withdrawn from each 
subject and divided into the vacutainers for assessment 
of the following: fasting plasma glucose (FPG), lipid pro-
file (triglycerides (TG), total cholesterol (TC), LDL- choles-
terol and HDL-cholesterol, blood urea, serum creatinine, 
CRP, AST and ALT activity which were analysed using 
a biochemical analyser (Dimension, Siemens, Germany) 
using reagent kits supplied by the manufacturer of the 
analyzer in addition to HbA1c percentage [which was 
performed using an automated high performance liquid 
chromatography (HPLC; Tosoh)] and molecular studies.
Molecular studies: included estimation of ABCC8 
gene expression via determination of ABCC8 mRNA 
level in peripheral blood mononuclear cells (PBMC) by 
real time PCR. Estimation of Notch 2 gene expression 
via determination of Notch 2 mRNA level in PBMC 
by real time PCR. Determination of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA level as 
a housekeeping gene in PBMC by real time PCR.
Calculations
Calculation of estimated GFR (eGFR) using CKD-EPI 
equation [14].
Relative expression of target genes (ABCC8 and 
Notch 2) was calculated using the comparative CT 
method (2–DDCT method). The method describes the 
change in expression of the target gene relative to 
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reference gene [15]. In the current study, the relative 
expression of (ABCC8 and Notch 2) genes is compared 
to a housekeeping gene which was Glyceraldhyde 
3-phosphate dehydrogenase gene. The relative gene 
expression is usually set to 1 for reference samples be-
cause DDCT is equal to 0 and therefore 2° is equal to 1. 
Accordingly, a value less than 1 is considered down 
expression while more than 1 is overexpression.
Statistical analysis
Data were fed to the computer and analyzed using 
IBM SPSS software package version 20.0. (Armonk, NY: 
IBM Corp). The Kolmogorov-Smirnov test was used to 
verify the normality of distribution. Significance of the 
obtained results was judged at the 5% level The Student 
t-test was used for normally distributed quantitative 
variables, to compare between two studied groups 
while Mann-Whitney test was used for abnormally 
distributed quantitative variables. Correlations between 
quantitative continuous variables parameters were 
evaluated by multivariate regression analysis with 
analysis of Pearson’s coefficients. 
Results
Demographic data 
This study included 80 patients with T2DM includ-
ing 21 males and 19 females in the group of patients 
with T2DM with DKD, 23 males and 17 females in the 
group of patients with T2DM without DKD and 19 
males and 21 females in the control group.
The mean age of the studied subjects with T2DM 
was 53.93 ± 6.63 years and 51.37 ± 9.29 years in the 
control group. There was no statistically significant 
difference between the mean age of the three groups.
Patients with T2DM had higher BMI and WC com-
pared to control group (P = 0.001, 0.002 respectively) 
while there was no significant difference in BMI or WC 
between patients with DKD and those without DKD. 
Among the studied groups there was no significant dif-
ference regarding mean values of systolic and diastolic 
blood pressure. The main characteristics of the studied 
population are described in Table 1.
Laboratory investigations
Patients with T2DM had significantly higher levels 
of total cholesterol, triglycerides, LDL-C and CRP in 
addition to lower levels of HDL-C and eGFR compared 
to control group while there was no significant dif-
ference between them regarding serum creatinine, 
AST and ALT activity. On the other hand, patients with 
DKD had significantly higher levels of FPG, HbA1c, ACR, 
triglycerides, uACR, CRP and significantly lower eGFR 
compared to patients without DKD while there was 
no difference between both groups regarding serum 
creatinine, LDL-C, HDL-C, TC, ALT and AST activity. Basic 
laboratory investigations are shown in Table 2.
Table 1. Demographic data of studied population
Cases with T2DM Control (n = 40) P1 P2
Total  
(n = 80)
With DKD  
(n = 40)
Without DKD  
(n = 40)
No. %
No. % No. % No. %
Sex
Male 44 55.0 21 52.5 23 57.5 19 47.5 0.438 0.653
Female 36 45.0 19 47.5 17 42.5 21 52.5
Age (years)
Mean ± SD 53.93 ± 6.63 54.24 ± 10.18 54.08 ± 8.54 51.37 ± 9.29 0.127 0.986
BMI [kg/m2]
Mean ± SD 31.16 ± 3.57 31.34 ± 4.32 30.98 ± 2.67 27.37 ± 3.03 0.001 0.657
WC [cm]
Mean ± SD 116.0 ± 5.43 116.5 ± 5.82 114.98 ± 5.67 110.77 ± 5.79 0.002 0.2
Systolic blood pressure [mm Hg]
Mean ± SD 132.17 ± 11.94 133.81 ± 12.53 131.64 ± 10.38 131.5 ± 6.97 0.793 0.434
Diastolic blood pressure [mm Hg]
Mean ± SD 85.83 ± 8.42 87.25 ± 8.81 84.17 ± 9.22 82.33 ± 9.35 0.185 0.212
BMI — body mass index; WC — waist circumference; SD — standard deviation 
P1: P value for comparing between control and total cases 
P2: P value for comparing between patients with DKD and patients without DKD 
Statistically significant at P ≤ 0.05
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Gene expression studies
As regards ABCC8 gene, 92.5% (74/80) of the 
cases with T2DM showed overexpression while 7.5% 
of cases (6/80) showed downregulated expression in-
dicating higher expression of ABCC8 among patients 
with T2DM compared to controls. Also, there was 
a significant positive correlation between ABCC8 gene 
expression and HbA1c percentage (P = 0.006) while 
there was no significant correlation between ABCC8 
gene expression and other studied parameters. Also, 
there was no significant difference in the expression of 
ABCC8 gene between patients with DKD and patients 
without DKD (P = 0.931). 
Notch 2 gene showed upregulated expression in 
95% (76/80) of the cases with T2DM and this high 
expression was demonstrated in patients with DKD as 
97.5% (39/40) of them showed upregulated expression 
and also in patients without DKD showed upregulated 
expression of Notch 2 gene in 92.5% (37/40) of the 
cases.
Despite the fact that both groups showed over-
expression of Notch 2 gene in most of the cases, the 
expression of Notch 2 gene was significantly higher 
in patients with DKD compared to those without DKD 
(P = 0.017). Moreover, Notch 2 gene expression was 
significantly positively correlated with uACR, FPG and 
HbA1c percentage (P = 0.004, 0.15 and < 0.001 respec-
tively) and significantly negatively correlated with eGFR 
(P = 0.002) while it did not show any significant correla-
tion with other studied parameters. Expression of both 
genes among different groups are shown in Tables 3 
and 4 and correlation studies are shown in Table 5. 
Multivariate regression analysis showed that Notch 2 
gene expression was an independent factor associated 
with both increased uACR (P = 0.008) and reduced 
eGFR (P = 0.003).
Table 2. Basic laboratory parameters of the studied groups
Cases with T2DM Control  
Group
P1 P2
Total cases Patients with DKD Patients without DKD
ALT [U/L]
Mean ± SD 21 ± 6.9 22 ± 7.8 20 ± 5.4 19 ± 6.2 0.431 0.140
AST [U/L]
Mean ± SD 18 ± 5.8 19 ± 6.1 17 ± 4.7 17 ± 4.9 0.562 0.272
Triglycerides [mg/dL]
Mean ± SD 206.83 ± 66.42 233.17 ± 76.21 180.47 ± 41.28 121.20 ± 13.78 < 0.001 < 0.001
Total cholesterol [mg/dL]
Mean ± SD 213.69 ± 33.24 220.38 ± 30.77 207.0 ± 34.63 162.78 ± 21.51 < 0.001 0.110
HDL-C [mg/dL]
Mean ± SD 48.72 ± 9.59 46.55 ± 8.89 50.90 ± 9.88 55.78 ± 7.52 < 0.001 0.074
LDL-C [mg/dL]
Mean ± SD 138.80 ± 23.66 142.73 ± 24.85 134.88 ± 22.01 93.03 ± 15.45 < 0.001 0.225
Serum creatinine
Mean ± SD 0.79 ± 0.10 0.79–0.12 0.80 ± 0.07 0.7 ± 0.09 0.068 0.451
eGFR [ml/min/1.73 m2]
Mean ± SD 96.39 ± 10.92 93.88 ± 14.05 98.9 ± 5.60 116.68 ± 12.54 < 0.001 0.041
UACR [mg/gm. Cr]
Mean ± SD 123.99± 197.4 237.31 ± 229.1 10.68 ± 7.15 8.35 ± 4.8 < 0.001 < 0.001
HbA1c (%)
Mean ± SD 9.84 ± 2.37 10.83 ± 2.30 8.85 ± 2.03 5.16 ± 0.23 < 0.001 < 0.001
FPG [mg/dL]
Mean ± SD 207.0 ± 92.28 230.3 ± 78.12 183.6 ± 100.1 82.16 ± 8.64 < 0.001 0.023
CRP [mg/L]
Mean ± SD 50.69 ± 25.68 59.30 ± 22.25 42.08 ± 26.24 7.15 ± 2.88 < 0.001 0.011
ALT — alanine aminotransferase; AST — aspartate aminotransferase; CRP — C-reactive protein; eGFR — estimated glomerular filtration rate; FPG — fast-
ing plasma glucose; HbA1c — hemoglobin A1c; HDL-C — high-density lipoprotein cholesterol; LDL-C — low-density lipoprotein cholesterol; UACR — urinary 
albumin-to-creatinine ratio 
P1: P value for comparing between control and total cases 
P2: P value for comparing between patients with DKD and patients without DKD 
Statistically significant at P ≤ 0.05 
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Discussion
T2DM is considered a major health problem world-
wide. Several risk factors are known to be associated with 
increased risk of T2DM, including old age, obesity, increased 
intake of animal fats, sedentary lifestyle, presence of hy-
pertension, hyperlipidemia and positive family history [16].
DKD is an important microvascular complication 
of T2DM which is usually characterized by increasing 
urine albumin excretion accompanied by declining eGFR 
and it is considered a major cause of ESRD worldwide. 
ADA recommends to assess urinary albumin excretion 
and eGFR in all patients with T2DM at least annually 
for screening of DKD [6].
The last years have witnessed advances in our 
understanding of the genetic basis of T2DM and 
identification of multiple genetic variants that are as-
sociated with T2DM [17]. However, the role of most 
of the identified genetic variants in the pathogenesis 
of T2DM and its complications including DKD is still 
unclear. Moreover other factors seem to contribute to 
the pathogenesis of T2DM and DKD including possible 
unidentified genetic factors, unknown environmental 
and epigenetic factors.
ABCC8 gene provides instructions for making the 
sulfonylurea receptor 1 (SUR1) protein which is one 
subunit of the ATP-sensitive potassium (KATP) chan-
nel that is found across cell membranes in the beta 
cells of the pancreas [18]. The current study showed 
increased expression of ABCC8 gene in patients with 
T2DM compared to normal subjects. This relation may 
be explained by the fact that changes in the genes that 
code for potassium channel subunits are expected to 
change glucose homeostasis by compromising insulin 
secretion [19]. 
The results of previous studies investigating the 
association between ABCC8 gene and T2DM showed 
conflicting results with some studies showing no asso-
ciation between ABCC8 gene polymorphism and T2DM 
and other studies and meta-analyses demonstrated 
Table 5. Correlation between the expression of ABCC8 and 
Notch 2 and different studied parameters
Cases (n = 80) Fold change
Notch 2 Abcc8 
r P r P
BMI 0.027 0.814 –0.013 0.908
FPG 0.272 0.015* 0.100 0.375
HbA1C 0.534 < 0.001 0.308 0.006
UACR 0.316 0.004 0.147 0.193
Serum creatinine –0.085 0.455 0.047 0.679
Triglycerides 0.002 0.986 –0.217 0.053
eGFR –0.344 0.002 –0.140 0.215
Total cholesterol 0.159 0.159 –0.016 0.891
HDL-C 0.062 0.582 –0.114 0.315
LDL-C 0.166 0.142 –0.084 0.460
CRP 0.218 0.052 –0.071 0.533
BMI — body mass index; CRP — C-reactive protein; eGFR — estimated 
glomerular filtration rate; FPG — fasting plasma glucose; HbA1c — hemo-
globin A1c; HDL-C — high-density lipoprotein cholesterol; LDL-C — low-
-density lipoprotein cholesterol; UACR — urinary albumin-to-creatinine 
ratio; r — Pearson coefficient, statistically significant at P ≤ 0.05
Table 4. Comparison between the two groups according 
to the expression of ABCC8 and Notch 2 genes
Patients with  
DKD (n = 40)
Patients  
without  
DKD (n = 40)
P
ABCC8 gene
Mean ± SD 1.58 ± 0.86 1.46 ± 0.74 0.931
Median (IQR) 1.30 (1.09–1.75) 1.25 (1.09–1.68)
Notch 2 gene
Mean ± SD 1.83 ± 1.09 1.34 ± 0.61 0.017
Median (IQR) 1.65 (1.10–2.15) 1.29 (1.06–1.58)
P: P value for comparing between the studied groups. Statistically signifi-
cant at P ≤ 0.05
Table 3. Expression of ABCC8 and Notch 2 genes among studied groups
Cases
Total (n = 80) Patients with DKD (n = 40) Patients without DKD (n = 40)
No. % No. % No. %
ABCC8 gene
Down expression 6 7.5 2 5.0 4 10.0
Over expression 74 92.5 38 95.0 36 90.0
Notch 2 gene 
Down expression 4 5.0 1 2.5 3 7.5
Over expression 76 95.0 39 97.5 37 92.5
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significant associations of the ABCC8 gene with the 
susceptibility of T2DM. Vigi et al. [20] enrolled 210 
T2DM and 200 non-diabetic subjects for determining 
the role of polymorphism of ABCC8 gene in T2DM and 
the findings showed positive association. Another study 
by Sokolova et al. [21] included 1384 individuals with 
T2DM and 414 healthy individuals showed that genetic 
variation located in the ABCC8 region is associated 
with the development of T2DM. Another meta-analysis 
by Qin et al. [22] demonstrated that ABCC8 polymor-
phisms are associated with risk of T2DM in the global 
population. 
The current study also demonstrated a significant 
positive correlation between ABCC8 gene expression and 
HbA1c and this is the first study, up to our knowledge, 
to demonstrate this correlation in patients with T2DM. 
The results of the present study also showed no 
significant difference in the expression of ABCC8 gene 
in patients with DKD compared to those without DKD. 
There are very few studies that investigated the asso-
ciation between ABCC8 gene expression and chronic 
complications of T2DM. Stefanski et al. [23] conducted 
a study on 215 obese patients with T2DM and reported 
no association between the ABCC8 polymorphism gene 
and the prevalence of chronic diabetic complications 
in obese patients with long-term T2DM which is in 
agreement with the present work. 
Regarding Notch 2 gene, the current study showed 
increased expression of Notch 2 gene in patients with 
T2DM compared to normal subjects and there was 
a significant positive correlation between Notch 2 
gene expression and HbA1c and FPG indicating not 
only a possible role of Notch 2 gene expression in the 
pathogenesis of T2DM but also a negative impact of 
Notch 2 expression on glycemic control. 
A previous meta-analysis linked certain poly-
morphisms of Notch 2 gene to the development of 
T2DM [24]. Also, Kim et al. [25] explained that altered 
expression of Notch 2 is implicated in beta cell dedif-
ferentiation playing a role in islet beta cell regeneration 
incompetence by increasing apoptosis. 
The results of the present study showed that the 
expression of Notch 2 gene in patients with DKD was 
higher than those without DKD. Moreover, multivariate 
regression analysis showed that Notch 2 gene expres-
sion had an independent significant positive relation 
with uACR and an independent significant negative 
relation with eGFR indicating a possible role of Notch 2 
signaling in the development of DKD. Notch signaling 
may be induced in mature podocytes under certain 
pathologic conditions including exposure to high glu-
cose, VEGF or ischemia leading to increased expression 
of Jag1 as well as re-expression of low levels of Notch 
receptors including Notch 2. In mouse models, it seems 
clear that Notch signaling in the adult, injured glomeru-
lus is pathogenic and in rodents, blockade of Notch 
signaling decreased Notch target gene expression in the 
glomerulus and prevented diabetes-induced glomerulo-
sclerosis and podocyte loss by apoptosis [26]. In agree-
ment with current study, Bonegio and Susztak [27] 
showed that Notch signaling is usually inactive in 
adult kidney but their signaling is reactivated during 
course of diabetic nephropathy and it promotes glo-
merulosclerosis development via increasing glomerular 
expression of Notch ligand Jag1. Matoba et al. [28] who 
demonstrated that inhibiting Notch signaling pathway 
in DKD attenuated podocyte apoptosis. Another study 
by Murea et al. [29] which included a total of 86 biopsy 
samples from subjects with acquired kidney diseases 
including DKD and reported found that Notch 1 and 
Notch 2 are expressed on podocytes in proteinuric ne-
phropathies and their level of expression correlates with 
the amount of proteinuria (across all disease groups) 
indicating a possible relation between Notch pathway 
and renal pathologies other than DKD. Sharaf et al. [30] 
in demonstrated significant positive correlation be-
tween Notch 2 expression and albuminuria. 
The present work and the previously mentioned 
studies demonstrate that Notch activation may play 
a role in development of T2DM and DKD and Notch 
signaling blockade may provide a therapeutic goal for 
T2DM and DKD.
Conclusion
Increased expression of Notch 2 and ABCC8 genes 
may play a role in the pathogenesis of T2DM and they 
may contribute to poor control of glycemic state. 
Moreover, altered expression of Notch 2 may play a role 
in increased susceptibility to DKD and development of 
albuminuria in patients with T2DM. These results may 
indicate a possible role of these genes as diagnostic 
or therapeutic tools in T2DM or DKD. We recommend 
performing more studies with larger sample sizes and 
a wider genetic panel to study the expression of dif-
ferent genes in T2DM and its complications, including 
ABCC 8 and Notch 2, and the possibility of targeting 
these genes as a therapeutic tool.
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